Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BKM120+ MEK162 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| BKM120 + MEK162 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BKM120 + MEK162 | DRUG | - |
Inclusion Criteria: * Histologically/ cytologically confirmed, advanced non resectable solid tumors * Measurable or non-measurable, but evaluable disease as determined by RECIST Exclusion Criteria: * Patients with primary CNS tumor or CNS tumor involvement. * Diabetes mellitus * Unacceptable ocul...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BKM120+ MEK162 is an investigational combination of two small molecules being studied for the treatment of advanced solid tumors. It is intended for patients with selected solid tumors that have progressed despite prior therapy. The combination is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
BKM120+ MEK162 combines two targeted small molecule agents. BKM120 is a PI3K inhibitor, and MEK162 is a MEK inhibitor. By blocking these two signaling pathways, the combination aims to inhibit tumor cell growth and survival in advanced solid tumors. The exact mechanism of action is under investigation in clinical trials.
BKM120+ MEK162 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the safety and efficacy of this combination in patients with advanced solid tumors.
BKM120+ MEK162 is in Phase 1 clinical development. It is an investigational combination therapy that has not yet been approved by the FDA or other regulatory agencies. The Phase 1 trial is designed to assess safety, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors.
BKM120+ MEK162 has been studied in one completed Phase 1 clinical trial with the identifier NCT01363232. The trial, titled 'Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients,' enrolled 89 participants across multiple countries including the United States, Canada, Germany, and others.
BKM120+ MEK162 is a combination of two drugs: BKM120 (buparlisib) and MEK162 (binimetinib). These are the generic names for the individual agents. The combination is being studied together for advanced solid tumors, but each drug is also developed separately for other indications.